BioCardia BCDA 深 滬
等待開盤 11-04 09:30:00 美东时间
0.9216
+0.020
+2.18%
華盛通- 最 高0.978
- 今 開0.9362
- 成交量 7.15万股
- 最 低 0.9026
- 昨 收 0.9019
- 總市值 1395.19万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 0.75
- 委 比 0.00%
- 總股本 1513.88万
- 歷史最高 129.00
- 量 比 1.34
- 振 幅 8.36%
- 歷史最低 0.75
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia收涨2.81%，成交额1.85万美元
10月29日，BioCardia（BCDA）收涨2.81%，报0.95美元，成交额1.85万美元，市值1434.25万美元。 行情数据 • 开盘价：0.93美元...
10-29 07:48
BioCardia收跌2.12%，成交额11.54万美元
10月27日，BioCardia（BCDA）收跌2.12%，报0.9美元，成交额11.54万美元，市值1364.76万美元。 行情数据 • 开盘价：0.93美元...
10-27 07:54
BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter ("Helix") intended for therapeutic and di...
10-19 21:16
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
BioCardia announced that the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter, intended for therapeutic and diagnostic agent delivery. FDA identified two pathways for clearance, with no concerns raised about safety, performance, or compatibility. The revised pre-submission, incorporating FDA feedback, was accepted in September 2026. BioCardia expects written feedback and a meeting this quarter to discuss a...
10-19 13:15
BioCardia收跌1.96%，成交额9.63万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:58
BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for...
10-01 21:16
BioCardia Advances Regulatory Milestones for Cardiovascular Therapies
BioCardia ( ($BCDA) ) has issued an update. On September 23, 2026, BioCardia re...
09-23 21:51
BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones. BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and ...
09-23 21:17
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia, a leader in cellular therapies for cardiovascular diseases, has announced key milestones. The CardiAMP therapy for ischemic heart failure is targeting a regulatory submission in Japan by Q4 2026, with potential market clearance by Q4 2027. The confirmatory CardiAMP HF II clinical study is enrolling patients in the U.S. Meanwhile, BioCardia plans to submit a De Novo pre-submission for its Helix delivery system to the FDA this quarter. F...
09-23 13:15
BioCardia Shares Fall 10% After Hours: Here's Why
BioCardia Inc. (NASDAQ:BCDA) shares fell 10.19% to $0.97 in after-hours trading Monday. BioCardia is a biotechnology company developing cell therapies for cardiovascular diseases. Nasdaq Compliance BioCardia said Nasdaq notified the company that it had regained compliance with the $1 minimum bid pri...
09-22 13:35
